Making the Switch: Biosimilar Infliximab in the Treatment of Inflammatory Bowel Disease - Certificate of Completion

Duration

1 hr

Profession

Specialist

# of Credits

1.0

Accreditation

Certificate of Completion

Expiry Date

2020-12-01

The advent of novel biologic medicines for the treatment of inflammatory bowel disease (IBD) has increased the availability of therapeutic options to induce and maintain remission in patients with this disease. They have become an important modality of treatment in IBD and the mainstay of therapy in patients with fistulising or perianal Crohn’s disease (CD).

Fellows of The Royal Australasian College of Physicians (RACP) can claim CPD credits in MyCPD for participation in this course. www.racp.edu.au/mycpd (log in to MyCPD) This interactive online learning activity is valued at 1Hour(s) of continuing education.

Lena Thin
MBBS, FRACP, MClinRes,
Harry Perkins Institute of Medical Research,
Western Australia Department of Health,
Fiona Stanley Hospital,
Perth, Western Australia

Miles Sparrow
Associate Professor
MBBS, PhD, FRACP
Director, Inflammatory Bowel Disease Unit
The Alfred Hospital, Melbourne, VIC
Monash University, Melbourne, VIC

Après avoir complété ce programme, le participant sera en mesure de :

  • Expliquer l’importance particulière de l’immunisation contre la grippe chez les enfants âgés de 6 mois à 2 ans
  • Offrir de manière efficace et efficiente l’immunisation contre la grippe aux parents d’enfants âgés de 6 mois à 2 ans
  • Adresser les hésitations des parents au sujet de la vaccination et minimiser la douleur lors de l’immunisation contre la grippe
  • Fournir l’immunisation contre la grippe à cette population selon les lignes directrices canadiennes


Related Courses